spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Cambridge Antibody Technology 

 HSMN NewsFeed - 6 Dec 2019
Apexigen Expands Leadership Team with Two Key Appointments in CMC and Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Aug 2013
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Feb 2013
EpiCept Corporation and Immune Pharmaceuticals Amend Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Nov 2012
Immune Pharmaceuticals and EpiCept Corporation Agree to Merge
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 May 2012
Creabilis Appoints Dr Simon Russell as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Sep 2011
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2009
Nabriva Therapeutics Appoints Dr David Chiswell as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Sep 2008
4-Antibody Appoints Dr. Richard Mason as New Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2008
Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 May 2008
MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2008
SV Life Sciences Appoints Dr. Hamish Cameron as Venture Partner
Venture Capital Personnel
 HSMN NewsFeed - 20 Dec 2007
MedImmune Expands Scientific and Engineering Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Oct 2007
AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Biopharmaceuticals
 HSMN NewsFeed - 18 Jun 2007
Vegenics Licenses From CoGenesys Antibodies Against VEGF-C for Applications Including Oncology
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Jun 2007
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B(R) Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 30 May 2007
Human Genome Sciences and GlaxoSmithKline Initiate Second Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 23 Apr 2007
Astrazeneca to Acquire Medimmune for $58 Per Share in a Fully Recommended, All-Cash Transaction with a Total Enterprise Value of $15.2 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Feb 2007
Human Genome Sciences and GlaxoSmithKline Announce Initiation of Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 5 Feb 2007
AstraZeneca Licenses Regeneron's VelocImmune(R) Technology for Discovering Human Monoclonal Antibodies
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Jan 2007
Cambridge Antibody Technology Licenses Monoclonal Antibody (CAT-213) for Treatment of Allergy Disorders to iCo Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Dec 2006
Cambridge Antibody Technology Announces Senior Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2006
Human Genome Sciences Announces Positive 76-Week Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2006
Royalty Pharma Announces Agreement Regarding the Purchase of the Rights to a Pre-Existing Royalty Interest in HUMIRA(R) From AstraZeneca and CAT
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2006
Human Genome Sciences Announces Positive Special Protocol Assessment From FDA for Phase 3 Clinical Trials of LymphoStat-B(TM) In Systemic Lupus Erythematosus
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Aug 2006
Human Genome Sciences Announces Phase 3 Clinical Development Program for LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2006
Human Genome Sciences Announces Full Presentation of Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 9 Jan 2006
CancerVax and Micromet Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
Return to NewsFeed  

 Additional items found! 52

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 52 additional stories matching:
Cambridge Antibody Technology
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.